455 results on '"Sutherland E"'
Search Results
2. Lipoxin Generation Is Related to Soluble Epoxide Hydrolase Activity in Severe Asthma
- Author
-
Ono, Emiko, Dutile, Stefanie, Kazani, Shamsah, Wechsler, Michael E, Yang, Jun, Hammock, Bruce D, Douda, David Nobuhiro, Tabet, Yacine, Khaddaj-Mallat, Rayan, Sirois, Marco, Sirois, Chantal, Rizcallah, Edmond, Rousseau, Éric, Martin, Richard, Sutherland, E Rand, Castro, Mario, Jarjour, Nizar N, Israel, Elliot, and Levy, Bruce D
- Subjects
Medical Biotechnology ,Biomedical and Clinical Sciences ,Lung ,Clinical Research ,Asthma ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,2.1 Biological and endogenous factors ,Aetiology ,Respiratory ,Adult ,Biomarkers ,Bronchoalveolar Lavage Fluid ,Case-Control Studies ,Epoxide Hydrolases ,Female ,Flow Cytometry ,Humans ,Lipoxins ,Male ,Middle Aged ,Oxidative Stress ,Severity of Illness Index ,Sputum ,Tumor Necrosis Factor-alpha ,resolution ,asthma ,pro-resolving mediators ,inflammation ,National Heart ,Lung ,and Blood Institute's Asthma Clinical Research Network ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
RationaleSevere asthma is characterized by airway inflammatory responses associated with aberrant metabolism of arachidonic acid. Lipoxins (LX) are arachidonate-derived pro-resolving mediators that are decreased in severe asthma, yet mechanisms for defective LX biosynthesis and a means to increase LXs in severe asthma remain to be established.ObjectivesTo determine if oxidative stress and soluble epoxide hydrolase (sEH) activity are linked to decreased LX biosynthesis in severe asthma.MethodsAliquots of blood, sputum, and bronchoalveolar lavage fluid were obtained from asthma subjects for mediator determination. Select samples were exposed to t-butyl-hydroperoxide or sEH inhibitor (sEHI) before activation. Peripheral blood leukocyte-platelet aggregates were monitored by flow cytometry, and bronchial contraction was determined with cytokine-treated human lung sections.Measurements and main results8-Isoprostane levels in sputum supernatants were inversely related to LXA4 in severe asthma (r = -0.55; P = 0.03) and t-butyl-hydroperoxide decreased LXA4 and 15-epi-LXA4 biosynthesis by peripheral blood leukocytes. LXA4 and 15-epi-LXA4 levels were inversely related to sEH activity in sputum supernatants and sEHIs significantly increased 14,15-epoxy-eicosatrienoic acid and 15-epi-LXA4 generation by severe asthma whole blood and bronchoalveolar lavage fluid cells. The abundance of peripheral blood leukocyte-platelet aggregates was related to asthma severity. In a concentration-dependent manner, LXs significantly inhibited platelet-activating factor-induced increases in leukocyte-platelet aggregates (70.8% inhibition [LXA4 100 nM], 78.3% inhibition [15-epi-LXA4 100 nM]) and 15-epi-LXA4 markedly inhibited tumor necrosis factor-α-induced increases in bronchial contraction.ConclusionsLX levels were decreased by oxidative stress and sEH activity. Inhibitors of sEH increased LXs that mediated antiphlogistic actions, suggesting a new therapeutic approach for severe asthma. Clinical trial registered with www.clinicaltrials.gov (NCT 00595114).
- Published
- 2014
3. Effect of Vitamin D3 on Asthma Treatment Failures in Adults With Symptomatic Asthma and Lower Vitamin D Levels: The VIDA Randomized Clinical Trial
- Author
-
Castro, Mario, King, Tonya S, Kunselman, Susan J, Cabana, Michael D, Denlinger, Loren, Holguin, Fernando, Kazani, Shamsah D, Moore, Wendy C, Moy, James, Sorkness, Christine A, Avila, Pedro, Bacharier, Leonard B, Bleecker, Eugene, Boushey, Homer A, Chmiel, James, Fitzpatrick, Anne M, Gentile, Deborah, Hundal, Mandeep, Israel, Elliot, Kraft, Monica, Krishnan, Jerry A, LaForce, Craig, Lazarus, Stephen C, Lemanske, Robert, Lugogo, Njira, Martin, Richard J, Mauger, David T, Naureckas, Edward, Peters, Stephen P, Phipatanakul, Wanda, Que, Loretta G, Sheshadri, Ajay, Smith, Lewis, Solway, Julian, Sullivan-Vedder, Lisa, Sumino, Kaharu, Wechsler, Michael E, Wenzel, Sally, White, Steven R, and Sutherland, E Rand
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Asthma ,Clinical Trials and Supportive Activities ,Complementary and Integrative Health ,Nutrition ,Clinical Research ,Lung ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Respiratory ,Administration ,Inhalation ,Administration ,Oral ,Adrenal Cortex Hormones ,Adult ,Anti-Asthmatic Agents ,Cholecalciferol ,Dose-Response Relationship ,Drug ,Double-Blind Method ,Female ,Glucocorticoids ,Humans ,Male ,Middle Aged ,Pregnenediones ,Treatment Failure ,Vitamin D Deficiency ,Vitamins ,National Heart ,Lung ,and Blood Institute’s AsthmaNet ,Medical and Health Sciences ,General & Internal Medicine ,Biomedical and clinical sciences ,Health sciences - Abstract
ImportanceIn asthma and other diseases, vitamin D insufficiency is associated with adverse outcomes. It is not known if supplementing inhaled corticosteroids with oral vitamin D3 improves outcomes in patients with asthma and vitamin D insufficiency.ObjectiveTo evaluate if vitamin D supplementation would improve the clinical efficacy of inhaled corticosteroids in patients with symptomatic asthma and lower vitamin D levels.Design, setting, and participantsThe VIDA (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma) randomized, double-blind, parallel, placebo-controlled trial studying adult patients with symptomatic asthma and a serum 25-hydroxyvitamin D level of less than 30 ng/mL was conducted across 9 academic US medical centers in the National Heart, Lung, and Blood Institute's AsthmaNet network, with enrollment starting in April 2011 and follow-up complete by January 2014. After a run-in period that included treatment with an inhaled corticosteroid, 408 patients were randomized.InterventionsOral vitamin D3 (100,000 IU once, then 4000 IU/d for 28 weeks; n = 201) or placebo (n = 207) was added to inhaled ciclesonide (320 µg/d). If asthma control was achieved after 12 weeks, ciclesonide was tapered to 160 µg/d for 8 weeks, then to 80 µg/d for 8 weeks if asthma control was maintained.Main outcomes and measuresThe primary outcome was time to first asthma treatment failure (a composite outcome of decline in lung function and increases in use of β-agonists, systemic corticosteroids, and health care).ResultsTreatment with vitamin D3 did not alter the rate of first treatment failure during 28 weeks (28% [95% CI, 21%-34%] with vitamin D3 vs 29% [95% CI, 23%-35%] with placebo; adjusted hazard ratio, 0.9 [95% CI, 0.6-1.3]). Of 14 prespecified secondary outcomes, 9 were analyzed, including asthma exacerbation; of those 9, the only statistically significant outcome was a small difference in the overall dose of ciclesonide required to maintain asthma control (111.3 µg/d [95% CI, 102.2-120.4 µg/d] in the vitamin D3 group vs 126.2 µg/d [95% CI, 117.2-135.3 µg/d] in the placebo group; difference of 14.9 µg/d [95% CI, 2.1-27.7 µg/d]).Conclusions and relevanceVitamin D3 did not reduce the rate of first treatment failure or exacerbation in adults with persistent asthma and vitamin D insufficiency. These findings do not support a strategy of therapeutic vitamin D3 supplementation in patients with symptomatic asthma.Trial registrationclinicaltrials.gov Identifier: NCT01248065.
- Published
- 2014
4. Comorbidities of COPD have a major impact on clinical outcomes, particularly in African Americans.
- Author
-
Putcha, Nirupama, Han, Meilan K, Martinez, Carlos H, Foreman, Marilyn G, Anzueto, Antonio R, Casaburi, Richard, Cho, Michael H, Hanania, Nicola A, Hersh, Craig P, Kinney, Gregory L, Make, Barry J, Steiner, Robert M, Lutz, Sharon M, Thomashow, Byron M, Williams, Andre A, Bhatt, Surya P, Beaty, Terri H, Bowler, Russell P, Ramsdell, Joe W, Curtis, Jeffrey L, Everett, Douglas, Hokanson, John E, Lynch, David A, Sutherland, E Rand, Silverman, Edwin K, Crapo, James D, Wise, Robert A, Regan, Elizabeth A, and Hansel, Nadia N
- Subjects
Epidemiology ,Health Sciences ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Lung ,Prevention ,Respiratory ,Good Health and Well Being ,COPD ,comorbidities ,race ,the COPDGene® Investigators ,Comorbidities ,Race - Abstract
BackgroundCOPD patients have a great burden of comorbidity. However, it is not well established whether this is due to shared risk factors such as smoking, if they impact patients exercise capacity and quality of life, or whether there are racial disparities in their impact on COPD.MethodsWe analyzed data from 10,192 current and ex-smokers with (cases) and without COPD (controls) from the COPDGene® cohort to establish risk for COPD comorbidities adjusted for pertinent covariates. In adjusted models, we examined comorbidities prevalence and impact in African-Americans (AA) and Non-Hispanic Whites (NHW).ResultsComorbidities are more common in COPD compared to those with normal spirometry (controls), and the risk persists after adjustments for covariates including pack-years smoked. After adjustment for confounders, eight conditions were independently associated with worse exercise capacity, quality of life and dyspnea. There were racial disparities in the impact of comorbidities on exercise capacity, dyspnea and quality of life, presence of osteoarthritis and gastroesophageal reflux disease having a greater negative impact on all three outcomes in AAs than NHWs (p
- Published
- 2014
5. Predictors of response to tiotropium versus salmeterol in asthmatic adults.
- Author
-
Peters, Stephen P, Bleecker, Eugene R, Kunselman, Susan J, Icitovic, Nikolina, Moore, Wendy C, Pascual, Rodolfo, Ameredes, Bill T, Boushey, Homer A, Calhoun, William J, Castro, Mario, Cherniack, Reuben M, Craig, Timothy, Denlinger, Loren C, Engle, Linda L, Dimango, Emily A, Israel, Elliot, Kraft, Monica, Lazarus, Stephen C, Lemanske, Robert F, Lugogo, Njira, Martin, Richard J, Meyers, Deborah A, Ramsdell, Joe, Sorkness, Christine A, Sutherland, E Rand, Wasserman, Stephen I, Walter, Michael J, Wechsler, Michael E, Chinchilli, Vernon M, Szefler, Stanley J, and National Heart, Lung, and Blood Institute's Asthma Clinical Research Network
- Subjects
National Heart ,Lung ,and Blood Institute's Asthma Clinical Research Network ,Humans ,Asthma ,Albuterol ,Scopolamine Derivatives ,Bronchodilator Agents ,Anti-Asthmatic Agents ,Prognosis ,Treatment Outcome ,Cross-Over Studies ,Adult ,Middle Aged ,Female ,Male ,Adrenergic beta-2 Receptor Agonists ,Tiotropium Bromide ,Salmeterol Xinafoate ,ACD ,ACRN ,Asthma Clinical Research Network ,Asthma control day ,FVC ,Forced vital capacity ,HFA ,Hydrofluoroalkane ,ICS ,Inhaled corticosteroid ,LABA ,LAMA ,Long-acting muscarinic antagonist ,Long-acting β-agonist ,NHLBI ,National Heart ,Lung ,and Blood Institute ,OR ,Odds ratio ,PEF ,Peak expiratory flow ,TALC ,Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (ClinicalTrials.gov number ,NCT00565266) trial ,predictor of response ,responder analysis ,salmeterol ,tiotropium ,Clinical Research ,Lung ,Respiratory ,Immunology ,Allergy - Abstract
BackgroundTiotropium has activity as an asthma controller. However, predictors of a positive response to tiotropium have not been described.ObjectiveWe sought to describe individual and differential responses of asthmatic patients to salmeterol and tiotropium when added to an inhaled corticosteroid, as well as predictors of a positive clinical response.MethodsData from the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Research Network's Tiotropium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (ClinicalTrials.gov number, NCT00565266) trial were analyzed for individual and differential treatment responses to salmeterol and tiotropium and predictors of a positive response to the end points FEV1, morning peak expiratory flow (PEF), and asthma control days (ACDs).ResultsAlthough approximately equal numbers of patients showed a differential response to salmeterol and tiotropium in terms of morning PEF (n = 90 and 78, respectively) and ACDs (n = 49 and 53, respectively), more showed a differential response to tiotropium for FEV1 (n = 104) than salmeterol (n = 62). An acute response to a short-acting bronchodilator, especially albuterol, predicted a positive clinical response to tiotropium for FEV1 (odds ratio, 4.08; 95% CI, 2.00-8.31; P < .001) and morning PEF (odds ratio, 2.12; 95% CI, 1.12-4.01; P = 0.021), as did a decreased FEV1/forced vital capacity ratio (FEV1 response increased 0.39% of baseline for every 1% decrease in FEV1/forced vital capacity ratio). Higher cholinergic tone was also a predictor, whereas ethnicity, sex, atopy, IgE level, sputum eosinophil count, fraction of exhaled nitric oxide, asthma duration, and body mass index were not.ConclusionAlthough these results require confirmation, predictors of a positive clinical response to tiotropium include a positive response to albuterol and airway obstruction, factors that could help identify appropriate patients for this therapy.
- Published
- 2013
6. P2X7-Regulated Protection from Exacerbations and Loss of Control Is Independent of Asthma Maintenance Therapy
- Author
-
Denlinger, Loren C, Manthei, David M, Seibold, Max A, Ahn, Kwangmi, Bleecker, Eugene, Boushey, Homer A, Calhoun, William J, Castro, Mario, Chinchili, Vernon M, Fahy, John V, Hawkins, Greg A, Icitovic, Nicolina, Israel, Elliot, Jarjour, Nizar N, King, Tonya, Kraft, Monica, Lazarus, Stephen C, Lehman, Erik, Martin, Richard J, Meyers, Deborah A, Peters, Stephen P, Sheerar, Dagna, Shi, Lei, Sutherland, E Rand, Szefler, Stanley J, Wechsler, Michael E, Sorkness, Christine A, Lemanske, Robert F, and Investigators, the NHLBI Asthma Clinical Research Network
- Subjects
Asthma ,Clinical Research ,Lung ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Respiratory ,Adrenal Cortex Hormones ,Adult ,African Americans ,Albuterol ,Case-Control Studies ,Disease Progression ,Female ,Forced Expiratory Volume ,Humans ,Male ,Nuclear Pore ,Polymorphism ,Single Nucleotide ,Prednisone ,Receptors ,Purinergic P2X7 ,asthma ,P2X(7) ,exacerbation ,Asthma Clinical Research Network ,corticosteroids ,NHLBI Asthma Clinical Research Network Investigators ,Black or African American ,Medical and Health Sciences ,Respiratory System - Abstract
RationaleThe function of the P2X(7) nucleotide receptor protects against exacerbation in people with mild-intermittent asthma during viral illnesses, but the impact of disease severity and maintenance therapy has not been studied.ObjectivesTo evaluate the association between P2X(7), asthma exacerbations, and incomplete symptom control in a more diverse population.MethodsA matched P2RX7 genetic case-control was performed with samples from Asthma Clinical Research Network trial participants enrolled before July 2006, and P2X(7) pore activity was determined in whole blood samples as an ancillary study to two trials completed subsequently.Measurements and main resultsA total of 187 exacerbations were studied in 742 subjects, and the change in asthma symptom burden was studied in an additional 110 subjects during a trial of inhaled corticosteroids (ICS) dose optimization. African American carriers of the minor G allele of the rs2230911 loss-of-function single nucleotide polymorphism were more likely to have a history of prednisone use in the previous 12 months, with adjustment for ICS and long-acting β(2)-agonists use (odds ratio, 2.7; 95% confidence interval, 1.2-6.2; P = 0.018). Despite medium-dose ICS, attenuated pore function predicted earlier exacerbations in incompletely controlled patients with moderate asthma (hazard ratio, 3.2; confidence interval, 1.1-9.3; P = 0.033). After establishing control with low-dose ICS in patients with mild asthma, those with attenuated pore function had more asthma symptoms, rescue albuterol use, and FEV(1) reversal (P < 0.001, 0.03, and 0.03, respectively) during the ICS adjustment phase.ConclusionsP2X(7) pore function protects against exacerbations of asthma and loss of control, independent of baseline severity and the maintenance therapy.
- Published
- 2013
7. Comparison of Physician-, Biomarker-, and Symptom-Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adults With Asthma: The BASALT Randomized Controlled Trial
- Author
-
Calhoun, William J, Ameredes, Bill T, King, Tonya S, Icitovic, Nikolina, Bleecker, Eugene R, Castro, Mario, Cherniack, Reuben M, Chinchilli, Vernon M, Craig, Timothy, Denlinger, Loren, DiMango, Emily A, Engle, Linda L, Fahy, John V, Grant, J Andrew, Israel, Elliot, Jarjour, Nizar, Kazani, Shamsah D, Kraft, Monica, Kunselman, Susan J, Lazarus, Stephen C, Lemanske, Robert F, Lugogo, Njira, Martin, Richard J, Meyers, Deborah A, Moore, Wendy C, Pascual, Rodolfo, Peters, Stephen P, Ramsdell, Joe, Sorkness, Christine A, Sutherland, E Rand, Szefler, Stanley J, Wasserman, Stephen I, Walter, Michael J, Wechsler, Michael E, Boushey, Homer A, and Lung, and Blood Institute for the Asthma Clinical Research Network of the National Heart
- Subjects
Lung ,Asthma ,Clinical Research ,Clinical Trials and Supportive Activities ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Management of diseases and conditions ,7.3 Management and decision making ,Respiratory ,Administration ,Inhalation ,Adrenal Cortex Hormones ,Adult ,Biomarkers ,Breath Tests ,Double-Blind Method ,Female ,Humans ,Kaplan-Meier Estimate ,Male ,Middle Aged ,Nitric Oxide ,Practice Guidelines as Topic ,Respiratory Function Tests ,Treatment Failure ,Asthma Clinical Research Network of the National Heart ,Lung ,and Blood Institute ,Medical and Health Sciences ,General & Internal Medicine - Abstract
ContextNo consensus exists for adjusting inhaled corticosteroid therapy in patients with asthma. Approaches include adjustment at outpatient visits guided by physician assessment of asthma control (symptoms, rescue therapy, pulmonary function), based on exhaled nitric oxide, or on a day-to-day basis guided by symptoms.ObjectiveTo determine if adjustment of inhaled corticosteroid therapy based on exhaled nitric oxide or day-to-day symptoms is superior to guideline-informed, physician assessment-based adjustment in preventing treatment failure in adults with mild to moderate asthma.Design, setting, and participantsA randomized, parallel, 3-group, placebo-controlled, multiply-blinded trial of 342 adults with mild to moderate asthma controlled by low-dose inhaled corticosteroid therapy (n = 114 assigned to physician assessment-based adjustment [101 completed], n = 115 to biomarker-based [exhaled nitric oxide] adjustment [92 completed], and n = 113 to symptom-based adjustment [97 completed]), the Best Adjustment Strategy for Asthma in the Long Term (BASALT) trial was conducted by the Asthma Clinical Research Network at 10 academic medical centers in the United States for 9 months between June 2007 and July 2010.InterventionsFor physician assessment-based adjustment and biomarker-based (exhaled nitric oxide) adjustment, the dose of inhaled corticosteroids was adjusted every 6 weeks; for symptom-based adjustment, inhaled corticosteroids were taken with each albuterol rescue use.Main outcome measureThe primary outcome was time to treatment failure.ResultsThere were no significant differences in time to treatment failure. The 9-month Kaplan-Meier failure rates were 22% (97.5% CI, 14%-33%; 24 events) for physician assessment-based adjustment, 20% (97.5% CI, 13%-30%; 21 events) for biomarker-based adjustment, and 15% (97.5% CI, 9%-25%; 16 events) for symptom-based adjustment. The hazard ratio for physician assessment-based adjustment vs biomarker-based adjustment was 1.2 (97.5% CI, 0.6-2.3). The hazard ratio for physician assessment-based adjustment vs symptom-based adjustment was 1.6 (97.5% CI, 0.8-3.3).ConclusionAmong adults with mild to moderate persistent asthma controlled with low-dose inhaled corticosteroid therapy, the use of either biomarker-based or symptom-based adjustment of inhaled corticosteroids was not superior to physician assessment-based adjustment of inhaled corticosteroids in time to treatment failure.Trial registrationclinicaltrials.gov Identifier: NCT00495157.
- Published
- 2012
8. Hispanics taking tradipitant for motion sickness have a lower incidence of vomiting as compared to non-hispanics
- Author
-
Polymeropoulos, V., primary, Sutherland, E., additional, Pham, N., additional, Davis, T., additional, Bushman, M., additional, Xiao, C., additional, Polymeropoulos, C., additional, Birznieks, G., additional, and Polymeropoulos, M., additional
- Published
- 2023
- Full Text
- View/download PDF
9. Ethics of AI in Education: Towards a Community-Wide Framework
- Author
-
Holmes, W, Porayska-Pomsta, K, Holstein, K, Sutherland, E, Baker, T, Shum, SB, Santos, OC, Rodrigo, MT, Cukurova, M, Bittencourt, II, Koedinger, KR, Holmes, W, Porayska-Pomsta, K, Holstein, K, Sutherland, E, Baker, T, Shum, SB, Santos, OC, Rodrigo, MT, Cukurova, M, Bittencourt, II, and Koedinger, KR
- Abstract
While Artificial Intelligence in Education (AIED) research has at its core the desire to support student learning, experience from other AI domains suggest that such ethical intentions are not by themselves sufficient. There is also the need to consider explicitly issues such as fairness, accountability, transparency, bias, autonomy, agency, and inclusion. At a more general level, there is also a need to differentiate between doing ethical things and doing things ethically, to understand and to make pedagogical choices that are ethical, and to account for the ever-present possibility of unintended consequences. However, addressing these and related questions is far from trivial. As a first step towards addressing this critical gap, we invited 60 of the AIED community’s leading researchers to respond to a survey of questions about ethics and the application of AI in educational contexts. In this paper, we first introduce issues around the ethics of AI in education. Next, we summarise the contributions of the 17 respondents, and discuss the complex issues that they raised. Specific outcomes include the recognition that most AIED researchers are not trained to tackle the emerging ethical questions. A well-designed framework for engaging with ethics of AIED that combined a multidisciplinary approach and a set of robust guidelines seems vital in this context.
- Published
- 2022
10. Mixing performance and continuous production of nanomaterials in an advanced-flow reactor
- Author
-
Yang, M, Yang, L, Zheng, J, Hondow, N, Bourne, RA, Bailey, T, Irons, G, Sutherland, E, Lavric, D, and Wu, K-J
- Abstract
The Corning Advanced-FlowTM Reactor (AFR) whose productivity is ready for scale-up with limited loss of transport properties was implemented in the continuous synthesis of Ag nanoparticles (NPs). To demonstrate the effect of mixing on Ag NPs, the flow pattern and mixing characteristic (mainly on the meso- and macroscale) in AFR were studied by flow visualisation and computational fluid dynamics simulation first. It was found that increasing the total flow rate from 1 to 9 mL·min−1 could enhance mixing by the synergetic combination of secondary flows created by different mechanisms. The flow rate ratio in the range of 0.25–8 affected the degree of mixing by changing the initial concentration distribution profile across the combined stream. The highest degree of mixing was obtained at the flow rate ratios of 0.25 and 8. Subsequently, the micromixing performance was quantified by Villermaux-Dushman method. The micromixing time decreased from 17 to 4 ms as the total flow rate increased from 1 to 9 mL·min−1, while the micromixing time was nearly independent of the flow rate ratio. At last, the link between the mixing characteristics and average size and particle size distribution (PSD) of Ag NPs was established. As the total flow rate increased, the average particle size decreased, and PSD became narrower due to better micromixing efficiency. When the flow rate ratio varied, the PSD of Ag NPs was dependent on the width of the Ag precursor stream rather than the degree of mixing, because an excessive amount of NaBH4 was used.
- Published
- 2021
11. Biochemical Localization of Hepatic Surface-Membrane Na+,K+-ATPase Activity Depends on Membrane Lipid Fluidity
- Author
-
Sutherland, E., Dixon, B. S., Leffert, H. L., Skally, H., Zaccaro, L., and Simon, F. R.
- Published
- 1988
12. MacEdward Leach, 1892-1967
- Author
-
Greenway, John, Abrahams, Roger D., Alspach, Russell K., Beck, Horace P., Briggs, Katharine M., Browne, Ray B., Coffin, Tristram P., Dorson, Richard M., Fenton, William N., Garbáty, Thomas Jay, Gillmor, Frances, Glassie, Henry, Green, Archie, Hand, Wayland D., Jagendorf, Moritz, James, Thelma G., Johnson, Helen Sewell, Krappe, Edith S., Laws,, G. Malcolm, Luomala, Katharine, MacFadden,, Fred R., Richmond, W. Edson, Simeone, William E., Stekert, Ellen, Sutherland, E. V., Taylor, Archer, Thompson, Stith, and Utley, Francis Lee
- Published
- 1968
13. A New Enzymatic Assay for Guanosine 3 ′ :5 ′ -Cyclic Monophosphate and Its Application to the Ductus Deferens of the Rat
- Author
-
Schultz, G., Hardman, J. G., Schultz, K., Davis, J. W., and Sutherland, E. W.
- Published
- 1973
14. The Importance of Calcium Ions for the Regulation of Guanosine 3 ′ :5 ′ -cyclic Monophosphate Levels
- Author
-
Schultz, G., Hardman, J. G., Schultz, K., Baird, C. E., and Sutherland, E. W.
- Published
- 1973
15. Edward Cary Hayes, 1868-1928
- Author
-
Sutherland, E. H.
- Published
- 1929
16. Murder and the Death Penalty
- Author
-
Sutherland, E. H.
- Published
- 1925
- Full Text
- View/download PDF
17. Nitrous oxide-induced myeloneuropathy.
- Author
-
Swart G., Blair C., Lu Z., Yogendran S., Offord J., Sutherland E., Barnes S., Palavra N., Cremer P., Bolitho S., Michael Halmagyi G., Swart G., Blair C., Lu Z., Yogendran S., Offord J., Sutherland E., Barnes S., Palavra N., Cremer P., Bolitho S., and Michael Halmagyi G.
- Abstract
Background and purpose: Nitrous oxide misuse is a recognized issue worldwide. Prolonged misuse inactivates vitamin B12, causing a myeloneuropathy. Method(s): Twenty patients presenting between 2016 and 2020 to tertiary hospitals in Sydney with myeloneuropathy due to nitrous oxide misuse were reviewed. Result(s): The average age was 24 years, and mean canister consumption was 148 per day for 9 months. At presentation, paresthesias and gait unsteadiness were common, and seven patients were bedbound. Mean serum B12 was normal (258 pmol/L, normal range [NR] = 140-750) as was active B12 (87 pmol/L, normal > 35). In contrast, mean serum homocysteine was high (51 mumol/L, NR = 5-15). Spinal magnetic resonance imaging (MRI) showed characteristic dorsal column T2 hyperintensities in all 20 patients. Nerve conduction studies showed a predominantly axonal sensorimotor neuropathy (n = 5). Patients were treated with intramuscular vitamin B12, with variable functional recovery. Three of the seven patients who were bedbound at presentation were able to walk again with an aid at discharge. Of eight patients with follow-up data, most had persistent paresthesias and/or sensory ataxia. Mobility scores at admission and discharge were not significantly correlated with the serum total and active B12 levels or cumulative nitrous oxide use. There were no significant trends between serum active B12 level and cumulative nitrous oxide use (Spearman rho = -0.331, p = 0.195). Conclusion(s): Nitrous oxide misuse can cause a severe but potentially reversible subacute myeloneuropathy. Serum and active B12 can be normal, while elevated homocysteine and dorsal column high T2 signal on MRI strongly suggest the diagnosis. Neurological deficits can improve with abstinence and B12 supplementation, even in the most severely affected patients.Copyright © 2021 European Academy of Neurology.
- Published
- 2021
18. Patient perspectives of target weight management and ultrafiltration in haemodialysis: a multi-center survey.
- Author
-
Keane, D, Glyde, M, Dasgupta, I, Gardiner, C, Lindley, E, Mitra, S, Palmer, N, Dye, L, Wright, M, Sutherland, E, Keane, D, Glyde, M, Dasgupta, I, Gardiner, C, Lindley, E, Mitra, S, Palmer, N, Dye, L, Wright, M, and Sutherland, E
- Abstract
BACKGROUND: Decisions around planned ultrafiltration volumes are the only part of the haemodialysis prescription decided upon at every session. Removing too much fluid or too little is associated with both acute symptoms and long-term outcomes. The degree to which patients engage with or influence decision-making is not clear. We explored patient perspectives of prescribing ultrafiltration volumes, their understanding of the process and engagement with it. METHODS: A questionnaire developed for this study was administered to 1077 patients across 10 UK Renal Units. Factor analysis reduced the dataset into factors representing common themes. Relationships between survey results and factors were investigated using regression models. ANCOVA was used to explore differences between Renal Units. RESULTS: Patients generally felt in control of their fluid management and that they were given the final say on planned ultrafiltration volumes. Around half of the respondents reported they take an active role in their treatment. However, respondents were largely unable to relate signs and symptoms to fluid management practice and a third said they would not report common signs and symptoms to clinicians. A fifth of patients reported not to know how ultrafiltration volumes were calculated. Patients responded positively to questions relating to healthcare staff, though with significant variation between units, highlighting differences in perception of care. CONCLUSIONS: Despite a lack of formal acknowledgement in fluid management protocols, patients have significant involvement in decisions regarding fluid removal during dialysis. Furthermore, substantial gaps remain in patient knowledge and engagement. Formalizing the role of patients in these decisions, including patient education, may improve prescription and achievement of target weights.
- Published
- 2021
19. A cross-sectional study of knife injuries at a London major trauma centre
- Author
-
Pallett, J R, Sutherland, E, Glucksman, E, Tunnicliff, M, and Keep, J W
- Published
- 2014
- Full Text
- View/download PDF
20. Photoelectron studies of the liquid phase
- Author
-
Sutherland, E.
- Subjects
541 ,Physical chemistry - Published
- 1984
21. Survival of protozoa in cooling tower biocides
- Author
-
Sutherland, E E and Berk, S G
- Published
- 1996
- Full Text
- View/download PDF
22. PaCTS 1.0: A Crowdsourced Reporting Standard for Paleoclimate Data
- Author
-
Khider, D, Emile-Geay, J, McKay, NP, Gil, Y, Garijo, D, Ratnakar, V, Alonso-Garcia, M, Bertrand, S, Bothe, O, Brewer, P, Bunn, A, Chevalier, M, Comas-Bru, L, Csank, A, Dassié, E, DeLong, K, Felis, T, Francus, P, Frappier, A, Gray, W, Goring, S, Jonkers, L, Kahle, M, Kaufman, D, Kehrwald, NM, Martrat, B, McGregor, H, Richey, J, Schmittner, A, Scroxton, N, Sutherland, E, Thirumalai, K, Allen, K, Arnaud, F, Axford, Y, Barrows, T, Bazin, L, Pilaar Birch, SE, Bradley, E, Bregy, J, Capron, E, Cartapanis, O, Chiang, HW, Cobb, KM, Debret, M, Dommain, R, Du, J, Dyez, K, Emerick, S, Erb, MP, Falster, G, Finsinger, W, Fortier, D, Gauthier, N, George, S, Grimm, E, Hertzberg, J, Hibbert, F, Hillman, A, Hobbs, W, Huber, M, Hughes, ALC, Jaccard, S, Ruan, J, Kienast, M, Konecky, B, Le Roux, G, Lyubchich, V, Novello, VF, Olaka, L, Partin, JW, Pearce, C, Phipps, SJ, Pignol, C, Piotrowska, N, Poli, MS, Prokopenko, A, Schwanck, F, Stepanek, C, Swann, GEA, Telford, R, Thomas, E, Thomas, Z, Truebe, S, von Gunten, L, Waite, A, Weitzel, N, Wilhelm, B, Williams, J, Williams, JJ, Winstrup, M, Zhao, N, Zhou, Y, Khider, D, Emile-Geay, J, McKay, NP, Gil, Y, Garijo, D, Ratnakar, V, Alonso-Garcia, M, Bertrand, S, Bothe, O, Brewer, P, Bunn, A, Chevalier, M, Comas-Bru, L, Csank, A, Dassié, E, DeLong, K, Felis, T, Francus, P, Frappier, A, Gray, W, Goring, S, Jonkers, L, Kahle, M, Kaufman, D, Kehrwald, NM, Martrat, B, McGregor, H, Richey, J, Schmittner, A, Scroxton, N, Sutherland, E, Thirumalai, K, Allen, K, Arnaud, F, Axford, Y, Barrows, T, Bazin, L, Pilaar Birch, SE, Bradley, E, Bregy, J, Capron, E, Cartapanis, O, Chiang, HW, Cobb, KM, Debret, M, Dommain, R, Du, J, Dyez, K, Emerick, S, Erb, MP, Falster, G, Finsinger, W, Fortier, D, Gauthier, N, George, S, Grimm, E, Hertzberg, J, Hibbert, F, Hillman, A, Hobbs, W, Huber, M, Hughes, ALC, Jaccard, S, Ruan, J, Kienast, M, Konecky, B, Le Roux, G, Lyubchich, V, Novello, VF, Olaka, L, Partin, JW, Pearce, C, Phipps, SJ, Pignol, C, Piotrowska, N, Poli, MS, Prokopenko, A, Schwanck, F, Stepanek, C, Swann, GEA, Telford, R, Thomas, E, Thomas, Z, Truebe, S, von Gunten, L, Waite, A, Weitzel, N, Wilhelm, B, Williams, J, Williams, JJ, Winstrup, M, Zhao, N, and Zhou, Y
- Abstract
The progress of science is tied to the standardization of measurements, instruments, and data. This is especially true in the Big Data age, where analyzing large data volumes critically hinges on the data being standardized. Accordingly, the lack of community-sanctioned data standards in paleoclimatology has largely precluded the benefits of Big Data advances in the field. Building upon recent efforts to standardize the format and terminology of paleoclimate data, this article describes the Paleoclimate Community reporTing Standard (PaCTS), a crowdsourced reporting standard for such data. PaCTS captures which information should be included when reporting paleoclimate data, with the goal of maximizing the reuse value of paleoclimate data sets, particularly for synthesis work and comparison to climate model simulations. Initiated by the LinkedEarth project, the process to elicit a reporting standard involved an international workshop in 2016, various forms of digital community engagement over the next few years, and grassroots working groups. Participants in this process identified important properties across paleoclimate archives, in addition to the reporting of uncertainties and chronologies; they also identified archive-specific properties and distinguished reporting standards for new versus legacy data sets. This work shows that at least 135 respondents overwhelmingly support a drastic increase in the amount of metadata accompanying paleoclimate data sets. Since such goals are at odds with present practices, we discuss a transparent path toward implementing or revising these recommendations in the near future, using both bottom-up and top-down approaches.
- Published
- 2019
23. PaCTS 1.0: A Crowdsourced Reporting Standard for Paleoclimate Data
- Author
-
Khider, D., Emile-Geay, J., McKay, N. P., Gil, Y., Garijo, D., Ratnakar, V, Alonso-Garcia, M., Bertrand, S., Bothe, O., Brewer, P., Bunn, A., Chevalier, M., Comas-Bru, L., Csank, A., Dassie, E., DeLong, K., Felis, T., Francus, P., Frappier, A., Gray, W., Goring, S., Jonkers, L., Kahle, M., Kaufman, D., Kehrwald, N. M., Martrat, B., McGregor, H., Richey, J., Schmittner, A., Scroxton, N., Sutherland, E., Thirumalai, K., Allen, K., Arnaud, F., Axford, Y., Barrows, T., Bazin, L., Birch, S. E. Pilaar, Bradley, E., Bregy, J., Capron, E., Cartapanis, O., Chiang, H-W, Cobb, K. M., Debret, M., Dommain, R., Du, J., Dyez, K., Emerick, S., Erb, M. P., Falster, G., Finsinger, W., Fortier, D., Gauthier, Nicolas, George, S., Grimm, E., Hertzberg, J., Hibbert, F., Hillman, A., Hobbs, W., Huber, M., Hughes, A. L. C., Jaccard, S., Ruan, J., Kienast, M., Konecky, B., Le Roux, G., Lyubchich, V, Novello, V. F., Olaka, L., Partin, J. W., Pearce, C., Phipps, S. J., Pignol, C., Piotrowska, N., Poli, M-S, Prokopenko, A., Schwanck, F., Stepanek, C., Swann, G. E. A., Telford, R., Thomas, E., Thomas, Z., Truebe, S., von Gunten, L., Waite, A., Weitzel, N., Wilhelm, B., Williams, J., Winstrup, M., Zhao, N., Zhou, Y., Khider, D., Emile-Geay, J., McKay, N. P., Gil, Y., Garijo, D., Ratnakar, V, Alonso-Garcia, M., Bertrand, S., Bothe, O., Brewer, P., Bunn, A., Chevalier, M., Comas-Bru, L., Csank, A., Dassie, E., DeLong, K., Felis, T., Francus, P., Frappier, A., Gray, W., Goring, S., Jonkers, L., Kahle, M., Kaufman, D., Kehrwald, N. M., Martrat, B., McGregor, H., Richey, J., Schmittner, A., Scroxton, N., Sutherland, E., Thirumalai, K., Allen, K., Arnaud, F., Axford, Y., Barrows, T., Bazin, L., Birch, S. E. Pilaar, Bradley, E., Bregy, J., Capron, E., Cartapanis, O., Chiang, H-W, Cobb, K. M., Debret, M., Dommain, R., Du, J., Dyez, K., Emerick, S., Erb, M. P., Falster, G., Finsinger, W., Fortier, D., Gauthier, Nicolas, George, S., Grimm, E., Hertzberg, J., Hibbert, F., Hillman, A., Hobbs, W., Huber, M., Hughes, A. L. C., Jaccard, S., Ruan, J., Kienast, M., Konecky, B., Le Roux, G., Lyubchich, V, Novello, V. F., Olaka, L., Partin, J. W., Pearce, C., Phipps, S. J., Pignol, C., Piotrowska, N., Poli, M-S, Prokopenko, A., Schwanck, F., Stepanek, C., Swann, G. E. A., Telford, R., Thomas, E., Thomas, Z., Truebe, S., von Gunten, L., Waite, A., Weitzel, N., Wilhelm, B., Williams, J., Winstrup, M., Zhao, N., and Zhou, Y.
- Abstract
The progress of science is tied to the standardization of measurements, instruments, and data. This is especially true in the Big Data age, where analyzing large data volumes critically hinges on the data being standardized. Accordingly, the lack of community-sanctioned data standards in paleoclimatology has largely precluded the benefits of Big Data advances in the field. Building upon recent efforts to standardize the format and terminology of paleoclimate data, this article describes the Paleoclimate Community reporTing Standard (PaCTS), a crowdsourced reporting standard for such data. PaCTS captures which information should be included when reporting paleoclimate data, with the goal of maximizing the reuse value of paleoclimate data sets, particularly for synthesis work and comparison to climate model simulations. Initiated by the LinkedEarth project, the process to elicit a reporting standard involved an international workshop in 2016, various forms of digital community engagement over the next few years, and grassroots working groups. Participants in this process identified important properties across paleoclimate archives, in addition to the reporting of uncertainties and chronologies; they also identified archive-specific properties and distinguished reporting standards for new versus legacy data sets. This work shows that at least 135 respondents overwhelmingly support a drastic increase in the amount of metadata accompanying paleoclimate data sets. Since such goals are at odds with present practices, we discuss a transparent path toward implementing or revising these recommendations in the near future, using both bottom-up and top-down approaches.
- Published
- 2019
24. PaCTS 1.0: A Crowdsourced Reporting Standard for Paleoclimate Data
- Author
-
Martrat, Belen [0000-0001-9904-9178], Khider, Deborah, Emile-Geay, Julien, McKay, Nicholas P., Martrat, Belen, McGregor, Helen V., Scroxton, Nick, Sutherland, E., Thirumalai, Kaustubh, Allen, Kathryn J., Arnaud, Fabien, Axford, Yarrow L., Martrat, Belen [0000-0001-9904-9178], Khider, Deborah, Emile-Geay, Julien, McKay, Nicholas P., Martrat, Belen, McGregor, Helen V., Scroxton, Nick, Sutherland, E., Thirumalai, Kaustubh, Allen, Kathryn J., Arnaud, Fabien, and Axford, Yarrow L.
- Abstract
The progress of science is tied to the standardization of measurements, instruments, and data. This is especially true in the Big Data age, where analyzing large data volumes critically hinges on the data being standardized. Accordingly, the lack of community-sanctioned data standards in paleoclimatology has largely precluded the benefits of Big Data advances in the field. Building upon recent efforts to standardize the format and terminology of paleoclimate data, this article describes the Paleoclimate Community reporTing Standard (PaCTS), a crowdsourced reporting standard for such data. PaCTS captures which information should be included when reporting paleoclimate data, with the goal of maximizing the reuse value of paleoclimate data sets, particularly for synthesis work and comparison to climate model simulations. Initiated by the LinkedEarth project, the process to elicit a reporting standard involved an international workshop in 2016, various forms of digital community engagement over the next few years, and grassroots working groups. Participants in this process identified important properties across paleoclimate archives, in addition to the reporting of uncertainties and chronologies; they also identified archive-specific properties and distinguished reporting standards for new versus legacy data sets. This work shows that at least 135 respondents overwhelmingly support a drastic increase in the amount of metadata accompanying paleoclimate data sets. Since such goals are at odds with present practices, we discuss a transparent path toward implementing or revising these recommendations in the near future, using both bottom-up and top-down approaches. ©2019. American Geophysical Union. All Rights Reserved.
- Published
- 2019
25. Measuring sexual behaviour in the era of HIV/AIDS: the experience of Demographic and Health Surveys and similar enquiries
- Author
-
Curtis, S L and Sutherland, E G
- Published
- 2004
26. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis
- Author
-
Sutherland, E R, Allmers, H, Ayas, N T, Venn, A J, and Martin, R J
- Published
- 2003
27. Is Experimentation in Case Work Processes Desirable
- Author
-
Sutherland, E. H.
- Published
- 1928
- Full Text
- View/download PDF
28. Methodological Significance and Limitations of Specific Statistical Methods
- Author
-
Sutherland, E. H.
- Published
- 1929
- Full Text
- View/download PDF
29. CHALLENGING BEHAVIORS ON INPATIENT MEDICAL UNITS: INTEGRATED, NON-PHARMACOLOGICAL APPROACH FOR PATIENTS WITH DEMENTIA
- Author
-
Sutherland, E
- Subjects
Abstracts - Abstract
The San Francisco VA Health Care System (SFVAHCS) launched a taskforce to evaluate the needs of patients with complex medical and psychiatric needs that lead to extended hospital stays while focusing on improving quality of care, workplace safety, staff job satisfaction and decreasing length of stay/cost of hospitalization. Patients targeted for analysis were those with both dementia and behavioral challenges making placement outside of an acute hospital setting extremely difficult. Due to the outcomes the SFVAHCS initiated an innovative-best practice interdisciplinary mental health team to support patients, staff and families. The BEST Team (Behavioral Education and Support Team) is comprised of five team members and includes assessments, treatment planning, recommendations for care and patient/staff education. The BEST program collaborates with medical and surgical teams to offer education and assist with continuity of care of veterans with neurocognitive and behavioral challenges. The BEST also addresses length of stay, behavioral altercations, readmission, staff time off/turnover, staff satisfaction and feelings of safety, code greens, police standbys, and appropriate use of psychotropic meds when and if indicated. The BEST is an internationally-recognized, behavioral health team that is embedded within the acute inpatient medical environment to enhances quality of life, psychological well-being and behavioral function for our patients. BEST develops comprehensive treatment planning based on egalitarian interdisciplinary input while providing holistic, compassionate, and patient-centered health care.
- Published
- 2018
30. Direct comparison of distinct naive pluripotent states in human embryonic stem cells
- Author
-
Warrier, S., primary, Van der Jeught, M., additional, Duggal, G., additional, Tilleman, L., additional, Sutherland, E., additional, Taelman, J., additional, Popovic, M., additional, Lierman, S., additional, Chuva De Sousa Lopes, S., additional, Van Soom, A., additional, Peelman, L., additional, Van Nieuwerburgh, F., additional, De Coninck, D. I. M., additional, Menten, B., additional, Mestdagh, P., additional, Van de Sompele, J., additional, Deforce, D., additional, De Sutter, P., additional, and Heindryckx, B., additional
- Published
- 2017
- Full Text
- View/download PDF
31. Poster
- Author
-
Fiebig, H., Weber, B., Cromwell, O., Jutel, M., Fiedler, G., Hanschmann, H., Hansen, I., Stuck, B. A., Hörmann, K., Klimek, L., Jappe, U., Hoffmann, M., Burow, G., Mühlmeier, G., Maier, H., Mušič, E., Košnik, M., Piller, M., Drachenberg, K. J., Urban, E., Schenn, A., Ruëff, F., Weimer, G., Przybilla, B., Sieber, W., Schoppelrey, V., Pfeifer, M., Steiß, J. O., Lindemann, H., Wolf, H., Schnitker, J., Petermann, F., Bergmann, K. C., Zwacka, G., Steinert, B., Markert, U. R., Bijlsma, P. B., Backhaus, B., Weidenhiller, M., Donhauser, N., Hahn, E. G., Raithel, M., Erkelens, W., Hommes, D., Bruno, M., Akkerdaas, J., van Ree, R., Groot, J. A., Taminiau, J. A. J. M., Meinardi, M. M. H. M., Borowski, C., Schäfer, T., Eberhardt, F., Lepp, U., Becker, W.-M., Zabel, P., Hipler, U.-C., Spoo, J., Bauer, A., Elsner, P., Kuefner, M. A., Schwelberger, H. G., Lange, L., Rietschel, E., Riffelmann, F., Lauter, H., Müller, K.-M., Tränkner, A., Mach, K., Reulbach, U., Geyer, D., Leis, B., Ziegert, M., Ahlert, I., Deichmann, K. A., Heinzmann, A., Allmers, H., Beezhold, D., Hamilton, R. G., Sutherland, E. R., Schwanitz, H. J., Scherer, K., Bircher, A. J., Dymek, S., Lex, C., Balzer, S., Schuster, A., Hülsmeier, L., Barker, M., Müller-Lux, A., Göen, T., Koll, W., Koschel, D., Müller-Wening, D., Kütting, B., Janicke, N., Schippke, D., Langer, C., Schulz, T. G., Turowski, S., Drexler, H., Hallier, E., Bickeböller, H., Heutelbeck, A. R. R., Lässig, W., Nordwig, A., Dellweg, D., Schwarz, H., Goldmann, R., Lorenz, C., Achtzehn, U., Stehle, R., Keiper, B., Jilge, B., Beier, L., Schmidt, E. W., van Kampen, V., Haamann, F., Merget, R., Sander, I., Raulf-Heimsoth, M., Rabstein, S., Brüning, T., Ahrens, T., Muesken, H., Bergmann, K.-Ch., Vetter, M., Heitmann, M., Hunzelmann, N., Schuster, J., Kadar, J., Kespohl, S., Petersen, A., Meyer, H. E., Sickmann, A., Kleber, N., Hinrichs, J., Schocker, F., Becker, W. M., Rozynek, P., Dresselhaus, T., Reuter, B., Henzgen, M., Fahlbusch, B., Rudeschko, O., Schlenvoigt, G., Kroegel, C., Rihs, H.-P., Gaspar, Â., Pires, G., Hohenstein, E., Fiedler, E.-M., v. Pelchrzim, R., Focke, M., Zuberbier, T., Worm, M., Janowska, E., Grycmacher-Łapko, V., Kurek, M., Lippert, U., Niedenführ, S., Fuchs, T., Ludwig, A., Koch, A., Balda, B.-R., Oestmann, E., Philipp, S., Spornraft-Ragaller, P., Hammermann, J., Meurer, M., Ott, H., Wurpts, G., Krieg, R., Al Masaoudi, T., Joussen, S., Kiehl, K., Neis, M., Merk, H. F., Baron, J. M., Schmengler, J., John, S. M., Blaschke, V., Bonnekoh, B., Holzamer, N., Schmidt, U., Ambach, A., Oppermann, H., Thriene, B., Gollnick, H., Kraus, T., Häberle, M., Hoopmann, M., Hehl, O., Werfel, T., Heidrich, S., Kelber, J., Hünecke, P., Kasche, A., Klaus, S., Thiel, M., Buters, J., Weichenmeier, I., Ring, J., Traidl-Hoffmann, C., Behrendt, H., Krämer, U., Lau, S., Kim, S., Mahling, H., Schulz, G., Keil, T., Wahn, U., Mock, B., Kugler, J., Cremer, R., Sandner, B., Kaiser, F., Herbst, R. A., Wahl, R., Suck, R., Kügler, K., Frosch, P. J., Nabe, A., Konturek, P., Simon, K., Kressel, J., Nägel, A., Wilken, V., Strehfeld, T., Neubert, K., Pieper, B., Kuhn, M., Winterkamp, S., Pacurar, A., Senger, D., Beskitas, E., Dorrmann, H., Mueller, M. W., Harwanegg, C., Hiller, R., Kinne, R. W., Schröder, C. M., Mahler, V., Schröder, A., Erdmann, S., Schultis, H. W., Buchwald, F., Hampel, W., Maiss, J., Naegel, A., Zahradnik, E., Doekes, G., Runge, D. M., Schwertner, H., Grize, L., Schindler, C., Surber, Ch., Böckelmann, R., Horn, T., Breithaupt, S., Thiele, J. J., Gutermuth, J., Jakob, T., Heinzelmann, J., Varosi, F., Debevc, F., Pöhlmann, T. G., Seyfarth, L., Kindt, F., Löser, C., Niemeier, V., Gieler, U., Kummer, W., Haberberger, R. V., Klockenbring, T., Stöcker, M., Huhn, M., Bauer, R., Goerlich, R., Fischer, R., Barth, S., Suchodolska, A., Soost, S., Bayerl, C., Ludwig, B., Gancs, P., Häusermann, P., Harr, T., Müller, M., Sachs, B., Riegel, S., Schichler, D., Schrooten, J., Heussen, N., Hilgers, R.-D., Seo, J. W., Franke, I., and Strauss, R.
- Subjects
SIT und Insektengiftallergie ,Immunology and Allergy - Published
- 2004
- Full Text
- View/download PDF
32. Asthma Outcomes: Asthma Symptoms
- Author
-
Krishnan, Jerry A., Lemanske, Robert F., Canino, Glorisa J., Elward, Kurtis S., Kattan, Meyer, Matsui, Elizabeth C., Mitchell, Herman, Sutherland, E. Rand, and Minnicozzi, Michael
- Subjects
Adult ,Treatment Outcome ,Caregivers ,Child, Preschool ,Surveys and Questionnaires ,Outcome Assessment, Health Care ,Humans ,Child ,Severity of Illness Index ,Article ,Asthma ,Medical Records - Abstract
Respiratory symptoms are commonly used to assess the impact of patient-centered interventions.At the request of National Institutes of Health (NIH) institutes and other federal agencies, an expert group was convened to propose which measurements of asthma symptoms should be used as a standardized measure in future clinical research studies.Asthma symptom instruments were classified as daily diaries (prospectively recording symptoms between research visits) or retrospective questionnaires (completed at research visits). We conducted a systematic search in PubMed and a search for articles that cited key studies describing development of instruments. We classified outcome instruments as either core (required in future studies), supplemental (used according to study aims and standardized), or emerging (requiring validation and standardization). This work was discussed at an NIH-organized workshop in March 2010 and finalized in September 2011.Four instruments (3 daily diaries, 1 for adults and 2 for children; and 1 retrospective questionnaire for adults) were identified. Minimal clinically important differences have not been established for these instruments, and validation studies were only conducted in a limited number of patient populations. Validity of existing instruments may not be generalizable across racial-ethnic or other subgroups.An evaluation of symptoms should be a core asthma outcome measure in clinical research. However, available instruments have limitations that preclude selection of a core instrument. The working group participants propose validation studies in diverse populations, comparisons of diaries versus retrospective questionnaires, and evaluations of symptom assessment alone versus composite scores of asthma control.
- Published
- 2012
33. Is There a Link Between Obesity and Asthma?
- Author
-
Kim, Sang-Ha, primary, Sutherland, E. Rand, additional, and Gelfand, Erwin W., additional
- Published
- 2014
- Full Text
- View/download PDF
34. Evaluation of Affective Interactive Applications
- Author
-
Höök, Kristina, Isbister, Katherine, Westerman, Stephen, Gardner, Peter, Sutherland, E, Vasalou, E, Fagerberg Sundström, Petra, Kaye, Joseph, Laaksolahti, Jarmo, Höök, Kristina, Isbister, Katherine, Westerman, Stephen, Gardner, Peter, Sutherland, E, Vasalou, E, Fagerberg Sundström, Petra, Kaye, Joseph, and Laaksolahti, Jarmo
- Published
- 2011
35. Evaluation of Affective Interactive Applications
- Author
-
Höök, Kia, Isbister, K., Westerman, S., Gardner, P., Sutherland, E., Vasalou, A., Sundström, P., Kaye, J. J., Laaksolahti, Jarmo, Höök, Kia, Isbister, K., Westerman, S., Gardner, P., Sutherland, E., Vasalou, A., Sundström, P., Kaye, J. J., and Laaksolahti, Jarmo
- Abstract
Methods are developed for different audiences and purposes. HCI researchers develop methods to shape the future through pure, applied and blue sky research – as is still the case with most affective interactive applications. Unsurprisingly, practitioners will be more concerned that the methods they use not only are tractable but produce better and more innovative results in terms of the systems they ultimately release into the world. Researchers, on the other hand, may have other concerns, such as the novelty of their techniques. Up until recently, most HCI methods (both for researchers and practitioners) were developed for work applications and desktop situations. They focused on efficiency, learnability, transparency, control and other work-related values. They were developed in response to a theoretical orientation which viewed the user as an information processing system not so dissimilar to the computer itself. But now that HCI is concerned with technologies that enter all aspects of life, our methods have begun to change and will need to continue to change. In keeping with our changing conception of what a “user” is and a wider concern with their experience of use of new technologies, a key challenge will be to develop and expand methods for analyzing not just what people do with the technology but how it makes them feel, and not just how people understand technology but how they make sense of it as part of their lives. Methods must be concerned, not only with issues of usefulness and usability, but also with issues of aesthetics, expression, and emotion. In addition we need to focus on evaluating technology not just in the short term under controlled conditions but also in the longer term and in broader social and cultural contexts. In this section, we will therefore provide two strands of evaluation methods. The first concerns what we might see as more traditional usability evaluation: is my system usable for the purpose it was designed for? The second stran, QC 20220212
- Published
- 2011
- Full Text
- View/download PDF
36. The Effects of Airway Microbiome on Corticosteroid Responsiveness in Asthma
- Author
-
Goleva, Elena, primary, Jackson, Leisa P., additional, Harris, J. Kirk, additional, Robertson, Charles E., additional, Sutherland, E. Rand, additional, Hall, Clifton F., additional, Good, James T., additional, Gelfand, Erwin W., additional, Martin, Richard J., additional, and Leung, Donald Y. M., additional
- Published
- 2013
- Full Text
- View/download PDF
37. Modeling the Impact of Increased Adherence to Asthma Therapy
- Author
-
Schlender, Amory, primary, Alperin, Peter E., additional, Grossman, Helene L., additional, and Sutherland, E. Rand, additional
- Published
- 2012
- Full Text
- View/download PDF
38. Clinical Year in Review III
- Author
-
Sutherland, E. Rand, primary, Sciurba, Frank C., additional, Glazer, Craig S., additional, and Halpern, Scott D., additional
- Published
- 2012
- Full Text
- View/download PDF
39. Clinical Year in Review I
- Author
-
Kahn, Jeremy M., primary, Palmer, Scott M., additional, Spruit, Martijn A., additional, Punjabi, Naresh M., additional, and Sutherland, E. Rand, additional
- Published
- 2012
- Full Text
- View/download PDF
40. A Large Subgroup of Mild-to-Moderate Asthma Is Persistently Noneosinophilic
- Author
-
McGrath, Kelly Wong, primary, Icitovic, Nikolina, additional, Boushey, Homer A., additional, Lazarus, Stephen C., additional, Sutherland, E. Rand, additional, Chinchilli, Vernon M., additional, and Fahy, John V., additional
- Published
- 2012
- Full Text
- View/download PDF
41. Vitamin D and Asthma: Another Dimension
- Author
-
Gerber, Anthony N., primary and Sutherland, E. Rand, additional
- Published
- 2011
- Full Text
- View/download PDF
42. Impact of Race on Asthma Treatment Failures in the Asthma Clinical Research Network
- Author
-
Wechsler, Michael E., primary, Castro, Mario, additional, Lehman, Erik, additional, Chinchilli, Vernon M., additional, Sutherland, E. Rand, additional, Denlinger, Loren, additional, Lazarus, Stephen C., additional, Peters, Stephen P., additional, and Israel, Elliot, additional
- Published
- 2011
- Full Text
- View/download PDF
43. Clinical Year in Review IV:: Asthma, Chronic Obstructive Pulmonary Disease, Host-Microbe Interactions in Airways Disease, and Pulmonary Vascular Disease
- Author
-
Rand Sutherland, E., primary
- Published
- 2011
- Full Text
- View/download PDF
44. C-B3-02: Doctors' Role in Their Patient's Healing: Practices of the Highest Performing Physicians by Patient Survey
- Author
-
Janisse, T., primary, Sutherland, E., additional, Vuckovic, N., additional, Hsu, J., additional, Tallman, K., additional, and Frankel, R., additional
- Published
- 2010
- Full Text
- View/download PDF
45. Vitamin D Levels, Lung Function, and Steroid Response in Adult Asthma
- Author
-
Sutherland, E. Rand, primary, Goleva, Elena, additional, Jackson, Leisa P., additional, Stevens, Allen D., additional, and Leung, Donald Y. M., additional
- Published
- 2010
- Full Text
- View/download PDF
46. Safety and Efficacy of an Inhaled Epidermal Growth Factor Receptor Inhibitor (BIBW 2948 BS) in Chronic Obstructive Pulmonary Disease
- Author
-
Woodruff, Prescott G., primary, Wolff, Michael, additional, Hohlfeld, Jens M., additional, Krug, Norbert, additional, Dransfield, Mark T., additional, Sutherland, E. Rand, additional, Criner, Gerard J., additional, Kim, Victor, additional, Prasse, Antje, additional, Nivens, Michael C., additional, Tetzlaff, Kay, additional, Heilker, Ralf, additional, and Fahy, John V., additional
- Published
- 2010
- Full Text
- View/download PDF
47. PS1-32: Doctor's Role in Their Patient's Healing: Practices of the Highest Performing Physicians by Patient Survey
- Author
-
Sutherland, E., primary, Vuckovic, N., additional, Hsu, J., additional, Tallman, K., additional, Frankel, R., additional, Stein, T., additional, and Sung, S. H., additional
- Published
- 2010
- Full Text
- View/download PDF
48. Introduction and Perspective
- Author
-
Martin, R. J., primary, Kraft, M., additional, and Rand Sutherland, E., additional
- Published
- 2009
- Full Text
- View/download PDF
49. Body Mass and Glucocorticoid Response in Asthma
- Author
-
Sutherland, E. Rand, primary, Goleva, Elena, additional, Strand, Matthew, additional, Beuther, David A., additional, and Leung, Donald Y. M., additional
- Published
- 2008
- Full Text
- View/download PDF
50. Sham Procedure versus Usual Care as the Control in Clinical Trials of Devices: Which is Better?
- Author
-
Sutherland, E. R., primary
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.